KARD · CIK 0002123613
What Kardigan, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for KARD. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- contract manufacturing (Germany, Switzerland, Canada, China)medium
Owns no manufacturing; outsources all API and drug-product manufacturing to third-party CDMOs, including in Germany, Switzerland, Canada and China.
“We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties, including in jurisdictions outside of the United States such as Germany, Switzerland, Canada and China.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-price negotiationlow
Future product revenue exposed to IRA Medicare price negotiation and inflation-rebate regime for single-source drugs/biologics.
“The Inflation Reduction Act of 2022 (the “IRA”), among other things, directed HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and created civil monetary penalties and an excise tax for manufacturers that fail to comply with the drug price negotiation requirements.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Mayo Foundation for Medical Education and Research
“We also acquired rights to Ataciguat from Sanofi and the Mayo Foundation for Medical Education and Research (“Mayo”) through the acquisition of Rancho Santa Fe Bio, Inc. (“RSF”) and in-licensed Tonlamarsen from Ionis Pharmaceuticals, Inc. (“Ionis”).”
Cited →“We also acquired rights to Ataciguat from Sanofi and the Mayo Foundation for Medical Education and Research (“Mayo”) through the acquisition of Rancho Santa Fe Bio, Inc. (“RSF”) and in-licensed Tonlamarsen from Ionis Pharmaceuticals, Inc. (“Ionis”).”
Cited →“We also acquired rights to Ataciguat from Sanofi and the Mayo Foundation for Medical Education and Research (“Mayo”) through the acquisition of Rancho Santa Fe Bio, Inc. (“RSF”) and in-licensed Tonlamarsen from Ionis Pharmaceuticals, Inc. (“Ionis”).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch